Cargando…
Abnormal B cell glycosylation in autoimmunity: A new potential treatment strategy
Systemic lupus erythematosus (SLE) and primary Sjögren’s syndrome (pSS) are two autoimmune diseases characterised by the production of pathogenic autoreactive antibodies. Their aetiology is poorly understood. Nevertheless, they have been shown to involve several factors, such as infections and epige...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9453492/ https://www.ncbi.nlm.nih.gov/pubmed/36091064 http://dx.doi.org/10.3389/fimmu.2022.975963 |
_version_ | 1784785154379612160 |
---|---|
author | Morel, Marie Pochard, Pierre Echchih, Wiam Dueymes, Maryvonne Bagacean, Cristina Jousse-Joulin, Sandrine Devauchelle-Pensec, Valérie Cornec, Divi Jamin, Christophe Pers, Jacques-Olivier Bordron, Anne |
author_facet | Morel, Marie Pochard, Pierre Echchih, Wiam Dueymes, Maryvonne Bagacean, Cristina Jousse-Joulin, Sandrine Devauchelle-Pensec, Valérie Cornec, Divi Jamin, Christophe Pers, Jacques-Olivier Bordron, Anne |
author_sort | Morel, Marie |
collection | PubMed |
description | Systemic lupus erythematosus (SLE) and primary Sjögren’s syndrome (pSS) are two autoimmune diseases characterised by the production of pathogenic autoreactive antibodies. Their aetiology is poorly understood. Nevertheless, they have been shown to involve several factors, such as infections and epigenetic mechanisms. They also likely involve a physiological process known as glycosylation. Both SLE T cell markers and pSS-associated autoantibodies exhibit abnormal glycosylation. Such dysregulation suggests that defective glycosylation may also occur in B cells, thereby modifying their behaviour and reactivity. This study aimed to investigate B cell subset glycosylation in SLE, pSS and healthy donors and to extend the glycan profile to serum proteins and immunoglobulins. We used optimised lectin-based tests to demonstrate specific glycosylation profiles on B cell subsets that were specifically altered in both diseases. Compared to the healthy donor B cells, the SLE B cells exhibited hypofucosylation, whereas only the pSS B cells exhibited hyposialylation. Additionally, the SLE B lymphocytes had more galactose linked to N-acetylglucosamine or N-acetylgalactosamine (Gal-GlcNAc/Gal-GalNAc) residues on their cell surface markers. Interestingly, some similar alterations were observed in serum proteins, including immunoglobulins. These findings indicate that any perturbation of the natural glycosylation process in B cells could result in the development of pathogenic autoantibodies. The B cell glycoprofile can be established as a preferred biomarker for characterising pathologies and adapted therapeutics can be used for patients if there is a correlation between the extent of these alterations and the severity of the autoimmune diseases. |
format | Online Article Text |
id | pubmed-9453492 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-94534922022-09-09 Abnormal B cell glycosylation in autoimmunity: A new potential treatment strategy Morel, Marie Pochard, Pierre Echchih, Wiam Dueymes, Maryvonne Bagacean, Cristina Jousse-Joulin, Sandrine Devauchelle-Pensec, Valérie Cornec, Divi Jamin, Christophe Pers, Jacques-Olivier Bordron, Anne Front Immunol Immunology Systemic lupus erythematosus (SLE) and primary Sjögren’s syndrome (pSS) are two autoimmune diseases characterised by the production of pathogenic autoreactive antibodies. Their aetiology is poorly understood. Nevertheless, they have been shown to involve several factors, such as infections and epigenetic mechanisms. They also likely involve a physiological process known as glycosylation. Both SLE T cell markers and pSS-associated autoantibodies exhibit abnormal glycosylation. Such dysregulation suggests that defective glycosylation may also occur in B cells, thereby modifying their behaviour and reactivity. This study aimed to investigate B cell subset glycosylation in SLE, pSS and healthy donors and to extend the glycan profile to serum proteins and immunoglobulins. We used optimised lectin-based tests to demonstrate specific glycosylation profiles on B cell subsets that were specifically altered in both diseases. Compared to the healthy donor B cells, the SLE B cells exhibited hypofucosylation, whereas only the pSS B cells exhibited hyposialylation. Additionally, the SLE B lymphocytes had more galactose linked to N-acetylglucosamine or N-acetylgalactosamine (Gal-GlcNAc/Gal-GalNAc) residues on their cell surface markers. Interestingly, some similar alterations were observed in serum proteins, including immunoglobulins. These findings indicate that any perturbation of the natural glycosylation process in B cells could result in the development of pathogenic autoantibodies. The B cell glycoprofile can be established as a preferred biomarker for characterising pathologies and adapted therapeutics can be used for patients if there is a correlation between the extent of these alterations and the severity of the autoimmune diseases. Frontiers Media S.A. 2022-08-25 /pmc/articles/PMC9453492/ /pubmed/36091064 http://dx.doi.org/10.3389/fimmu.2022.975963 Text en Copyright © 2022 Morel, Pochard, Echchih, Dueymes, Bagacean, Jousse-Joulin, Devauchelle-Pensec, Cornec, Jamin, Pers and Bordron https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Morel, Marie Pochard, Pierre Echchih, Wiam Dueymes, Maryvonne Bagacean, Cristina Jousse-Joulin, Sandrine Devauchelle-Pensec, Valérie Cornec, Divi Jamin, Christophe Pers, Jacques-Olivier Bordron, Anne Abnormal B cell glycosylation in autoimmunity: A new potential treatment strategy |
title | Abnormal B cell glycosylation in autoimmunity: A new potential treatment strategy |
title_full | Abnormal B cell glycosylation in autoimmunity: A new potential treatment strategy |
title_fullStr | Abnormal B cell glycosylation in autoimmunity: A new potential treatment strategy |
title_full_unstemmed | Abnormal B cell glycosylation in autoimmunity: A new potential treatment strategy |
title_short | Abnormal B cell glycosylation in autoimmunity: A new potential treatment strategy |
title_sort | abnormal b cell glycosylation in autoimmunity: a new potential treatment strategy |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9453492/ https://www.ncbi.nlm.nih.gov/pubmed/36091064 http://dx.doi.org/10.3389/fimmu.2022.975963 |
work_keys_str_mv | AT morelmarie abnormalbcellglycosylationinautoimmunityanewpotentialtreatmentstrategy AT pochardpierre abnormalbcellglycosylationinautoimmunityanewpotentialtreatmentstrategy AT echchihwiam abnormalbcellglycosylationinautoimmunityanewpotentialtreatmentstrategy AT dueymesmaryvonne abnormalbcellglycosylationinautoimmunityanewpotentialtreatmentstrategy AT bagaceancristina abnormalbcellglycosylationinautoimmunityanewpotentialtreatmentstrategy AT joussejoulinsandrine abnormalbcellglycosylationinautoimmunityanewpotentialtreatmentstrategy AT devauchellepensecvalerie abnormalbcellglycosylationinautoimmunityanewpotentialtreatmentstrategy AT cornecdivi abnormalbcellglycosylationinautoimmunityanewpotentialtreatmentstrategy AT jaminchristophe abnormalbcellglycosylationinautoimmunityanewpotentialtreatmentstrategy AT persjacquesolivier abnormalbcellglycosylationinautoimmunityanewpotentialtreatmentstrategy AT bordronanne abnormalbcellglycosylationinautoimmunityanewpotentialtreatmentstrategy |